TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2644719

Group type: EXPERIMENTAL
Intervention: Intercostal blockade with bupivacaine supplemented with papaveretum
Number of subjects: 66

Group type: COMPARATOR
Intervention: Papaveretum alone
Number of subjects: 66
Study: 1035148

Group type: EXPERIMENTAL
Intervention: Vitamin A acid (retinoic acid)
Number of subjects: 405
Study: 31477178

Group type: EXPERIMENTAL
Intervention: EASE intervention (group-based, seven sessions for adolescents, three sessions for caregivers)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Enhanced usual care (one home-visit psychoeducation session)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: EASE intervention
Number of subjects: 445
Study: 28693854

Group type: EXPERIMENTAL
Intervention: bOPV and one dose of IPV
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: bOPV and two doses of IPV
Number of subjects: 939

Group type: COMPARATOR
Intervention: tOPV
Number of subjects: 939
Study: 25711726

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diazepam 10.0 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23078888

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 20689464

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19653786

Group type: EXPERIMENTAL
Intervention: Cocaine (175 mg, p.o.; 5 hourly doses; 875 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 16442902

Group type: EXPERIMENTAL
Intervention: Moderate drinking (7-13 drinks per week)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Low-dose warfarin or placebo
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Lovastatin in low or high doses
Number of subjects: 1351
Study: 15277738

Group type: EXPERIMENTAL
Intervention: Exercise training under supervision at the anaerobic threshold level for 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional walking regimen
Number of subjects: 36
Study: 11117101

Group type: EXPERIMENTAL
Intervention: Guided visualization tape
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual search task (Control)
Number of subjects: 0
Study: 9099773

Group type: EXPERIMENTAL
Intervention: Primary care (with care for acute illnesses also provided in the follow-up clinic)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Conventional care after nursery discharge (with well-baby care and care for chronic illnesses provided in our follow-up clinic)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Primary care
Number of subjects: 484
Study: 8360130

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g bid
Number of subjects: 393

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 0.5 g qid
Number of subjects: 393
Study: 3098997

Group type: EXPERIMENTAL
Intervention: Physical therapy thrice weekly (PT3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical therapy five times weekly (PT5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No therapy (controls)
Number of subjects: 30
Study: 31526206

Group type: EXPERIMENTAL
Intervention: Cabergoline (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27353076

Group type: EXPERIMENTAL
Intervention: External Hexagon (EH) implants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morse-Taper (MT) implants
Number of subjects: 12
Study: 25921850

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeDiet)
Number of subjects: 7447

Group type: COMPARATOR
Intervention: Control diet (advice on a low-fat diet)
Number of subjects: 7447
Study: 23476148

Group type: EXPERIMENTAL
Intervention: Proximal femur nail antirotation (PFNA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Reverse less invasive stabilisation system (LISS)
Number of subjects: 87
Study: 21610529

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 19170724

Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 52
Study: 16794641

Group type: EXPERIMENTAL
Intervention: Cervical traction at 7.5% total body weight (TBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical traction at 10% total body weight (TBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical traction at 15% total body weight (TBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical traction (all weights)
Number of subjects: 60
Study: 15486152

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (20 minutes daily for 7 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Shared activity with a registered nurse (20 minutes daily for 7 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard ward care
Number of subjects: 54
Study: 11685163

Group type: EXPERIMENTAL
Intervention: Cutting Balloon angioplasty (CBA)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 248
Study: 9129918

Group type: EXPERIMENTAL
Intervention: Nephrectomy
Number of subjects: 69

Group type: COMPARATOR
Intervention: No risk factors (control group)
Number of subjects: 69
Study: 8183657

Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected partner support group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-support control group
Number of subjects: 0
Study: 3282572

Group type: EXPERIMENTAL
Intervention: Filtered products
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard unfiltered products (Control)
Number of subjects: 40
Study: 31612292

Group type: EXPERIMENTAL
Intervention: Jacki Jacket (JJ)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 139
Study: 29882388

Group type: EXPERIMENTAL
Intervention: Immunotherapy treatments with various doses (specific dosages not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safe doses identified in the first stage of the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPIRIT trial design
Number of subjects: 0
Study: 27805299

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 129
Study: 24341527

Group type: EXPERIMENTAL
Intervention: 0.03 mg MRrhTSH
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.01 mg MRrhTSH
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.03 mg MRrhTSH (subgroup with basal (131)I uptake <20%)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.01 mg MRrhTSH (subgroup)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 95
Study: 22486146

Group type: EXPERIMENTAL
Intervention: 2.2 mm incision group
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3.0 mm incision group
Number of subjects: 60
Study: 20937921

Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaborative management of hypertension
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study: 18772809

Group type: EXPERIMENTAL
Intervention: ERG-jet electrode
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gold Foil electrode
Number of subjects: 27
Study: 15854463

Group type: EXPERIMENTAL
Intervention: Laparoscopy group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparotomy group
Number of subjects: 40
Study: 11170947

Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 537

Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 537
Study: 9510281

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg b.i.d.)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 8043291

Group type: EXPERIMENTAL
Intervention: Preconditioning (two 3-min periods of cross-clamping separated by 2 min of reperfusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (10 min cross-clamping with fibrillation without prior preconditioning)
Number of subjects: 20
Study: 3394980

Group type: EXPERIMENTAL
Intervention: 2 mg IM butorphanol
Number of subjects: 18

Group type: COMPARATOR
Intervention: 6 mg IM morphine
Number of subjects: 18
Study: 31811010

Group type: EXPERIMENTAL
Intervention: Internet-based warfarin anticoagulation management model
Number of subjects: 700

Group type: COMPARATOR
Intervention: Traditional outpatient anticoagulation management
Number of subjects: 700
Study: 28943074

Group type: EXPERIMENTAL
Intervention: MRI delineation (Center B, n=170, 7-mm margins)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Endorectal balloon (ERB) application (Center C, n=85, 7-mm margins)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (78 Gy in 39 fractions)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Hypofractionated radiation therapy (64.6 Gy in 19 fractions)
Number of subjects: 572
Study: 23301875

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (400 mg) and selenium (200 μg) supplementation for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20844095

Group type: EXPERIMENTAL
Intervention: Prehospital non-invasive ventilation (NIV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 36
Study: 19291083

Group type: EXPERIMENTAL
Intervention: 5-day communication course for clinicians
Number of subjects: 1395

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1395
Study: 16752942

Group type: COMPARATOR
Intervention: ASA 500 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ASA + EGb 761 240 mg
Number of subjects: 50
Study: 15087629

Group type: EXPERIMENTAL
Intervention: Intrathecal analgesia (bupivacaine 15 mg, clonidine 75 microg, morphine 0.2 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia supplemented with intravenous fentanyl
Number of subjects: 100
Study: 11576197

Group type: EXPERIMENTAL
Intervention: rizatriptan ODT 10-mg
Number of subjects: 524

Group type: COMPARATOR
Intervention: sumatriptan 50-mg tablet
Number of subjects: 524
Study: 9767742

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Preoperative erythropoietin therapy with acute normovolemic hemodilution
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study: 8144779

Group type: EXPERIMENTAL
Intervention: Active drug
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Active drug and Placebo
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: First drug tested
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Second drug tested
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Increased ventricular premature depolarizations
Number of subjects: 3840
Study: 2556484

Group type: EXPERIMENTAL
Intervention: Alfa LMWH 7500 anti-Xa coagulometric units twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: UFH 5000 IU t.i.d.
Number of subjects: 49
Study: 30891605

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in pregnancy (IPTp)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Parasitemia detected during pregnancy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Parasitemia detected only before the third trimester
Number of subjects: 637

Group type: COMPARATOR
Intervention: No parasitemia detected during pregnancy
Number of subjects: 637
Study: 28768800

Group type: EXPERIMENTAL
Intervention: Authorization to randomize in both trials
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Principal investigator specialties of interventional radiology and cardiology
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Pre‐trial reported performance >50 carotid angioplasty and stenting procedures per year
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Status in the top half of recruitment in the CREST trial
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Classification as a private health facility
Number of subjects: 147

Group type: COMPARATOR
Intervention: Participation in StrokeNet
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Median time between site selection to authorization to randomize
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Median time between authorization to randomize and a randomization
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 147
Study: 26049544

Group type: EXPERIMENTAL
Intervention: Nurse-delivered counselling intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 20
Study: 24134367

Group type: EXPERIMENTAL
Intervention: P4 for Women
Number of subjects: 134

Group type: COMPARATOR
Intervention: SISTA
Number of subjects: 134
Study: 21269509

Group type: EXPERIMENTAL
Intervention: DECISION+2 intervention group (experimental group)
Number of subjects: 700

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 700
Study: 19843681

Group type: EXPERIMENTAL
Intervention: E‐only (estrogen alone)
Number of subjects: 67412

Group type: EXPERIMENTAL
Intervention: E‐only for <5 years
Number of subjects: 67412

Group type: EXPERIMENTAL
Intervention: E‐only for >or=20 years
Number of subjects: 67412

Group type: EXPERIMENTAL
Intervention: E + P (estrogen plus progesterone)
Number of subjects: 67412

Group type: COMPARATOR
Intervention: Never used postmenopausal hormones
Number of subjects: 67412
Study: 16798698

Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg 3 times daily + S. boulardii 250 mg b.i.d. orally for 10 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Metronidazole 750 mg 3 times daily + placebo (empty capsules) for 10 days
Number of subjects: 65
Study: 15985128

Group type: EXPERIMENTAL
Intervention: Bupivacaine wound infiltration 0.5%; 10 mL, followed by continuous infusion: 10 mg/24 H
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 47
Study: 12660513

Group type: EXPERIMENTAL
Intervention: Tac triple therapy (n=185)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: ATG induction with tacrolimus (ATG-Tac, n=186)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: ATG induction with CsA (ATG-CsA, n=184)
Number of subjects: 555
Study: 10624454

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (440 IU) and Calcium (500 mg, 1250 mg calcium carbonate, Novartis) twice daily
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 248
Study: 8669348

Group type: EXPERIMENTAL
Intervention: Strength exercise group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mobility exercise group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 86
Study: 2172501

Group type: EXPERIMENTAL
Intervention: 2',3'-dideoxycytidine (ddC) at 0.015, 0.02, 0.03, and 0.04 mg/kg, given orally every 6 hours for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternating schedule of ddC for 1 week followed by AZT (180 mg/m2 every 6 hours) for 3 weeks
Number of subjects: 15
Study: 371371

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol, 50 mcg into each nostril four times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo aerosol therapy
Number of subjects: 30
Study: 31846113

Group type: EXPERIMENTAL
Intervention: Hip-focused exercise
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Knee-focused exercise
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Free physical activity
Number of subjects: 112
Study: 30817495

Group type: EXPERIMENTAL
Intervention: TTFields with maintenance TMZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 0
Study: 28055230

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 43

Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 43
Study: 25984803

Group type: EXPERIMENTAL
Intervention: Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 142
Study: 23765764

Group type: EXPERIMENTAL
Intervention: Pentax-AWS (AWS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (McL)
Number of subjects: 31
Study: 21244240

Group type: EXPERIMENTAL
Intervention: Synbiotic product (3 tablets per day, 2.4 × 10^9 colony-forming units/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Synbiotic product
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19591795

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine
Number of subjects: 0
Study: 17001106

Group type: EXPERIMENTAL
Intervention: GH treatment at 0.012 mg/kg/day for 24 weeks, followed by individualized dosing for another 24 weeks.
Number of subjects: 27
Study: 15799935

Group type: EXPERIMENTAL
Intervention: Endovascular repair (ER)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 342
Study: 10699140

Group type: EXPERIMENTAL
Intervention: Formula containing 12 mg/L of iron
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Formula containing 0.9 mg/L of iron
Number of subjects: 493

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 493
Study: 9489229

Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic procedures including blood tests, histologic examinations, instrumental investigations, and surgical interventions.
Number of subjects: 71
Study: 8268277

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 228392

Group type: EXPERIMENTAL
Intervention: Other hepatotoxic drugs
Number of subjects: 228392

Group type: EXPERIMENTAL
Intervention: Concomitant exposure to NSAIDs and other hepatotoxic drugs
Number of subjects: 228392

Group type: COMPARATOR
Intervention: Erythromycin estolate
Number of subjects: 228392

Group type: COMPARATOR
Intervention: Methyldopa, ampicillin, or NSAIDs
Number of subjects: 228392
Study: 3979013

Group type: EXPERIMENTAL
Intervention: Deactivation of cardiopulmonary receptors
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stimulation of cardiopulmonary receptors
Number of subjects: 9
Study: 29703007

Group type: EXPERIMENTAL
Intervention: 3 L PEG alone
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 2 L PEG plus 30 mL castor oil
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 1 L PEG, 30 mL castor oil and 5 g ascorbic acid
Number of subjects: 282
Study: 28216345

Group type: EXPERIMENTAL
Intervention: DSA followed by IVUS
Number of subjects: 100

Group type: COMPARATOR
Intervention: DSA alone
Number of subjects: 100
Study: 25918291

Group type: EXPERIMENTAL
Intervention: Onco‐Move (low‐intensity, home‐based physical activity program)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: OnTrack (moderate- to high-intensity, combined supervised resistance and aerobic exercise program)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 230
Study: 23971683

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy and parenting education program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfeeding interventions
Number of subjects: 0
Study: 21502292

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the lower limb motor cortex
Number of subjects: 0
Study: 18639302

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pelvic organ prolapse repair alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Urogenital Distress Inventory
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 47
Study: 17069098

Group type: EXPERIMENTAL
Intervention: CRX-675 (2, 20, 100, or 200 microg intranasally)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CRX-675 (100 microg)
Number of subjects: 28
Study: 12855210

Group type: EXPERIMENTAL
Intervention: Social support, affect, and exercise frequency
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Efficacy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Model
Number of subjects: 174
Study: 11497500

Group type: EXPERIMENTAL
Intervention: Botulinum toxin pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laser resurfacing (carbon dioxide or erbium laser)
Number of subjects: 10
Study: 9551706

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg t.i.d. pre- and co-treatment with cerivastatin 300 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cerivastatin 300 microg alone
Number of subjects: 12
Study: 8141156

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 92
Study: 3046554

Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate biweekly
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 25 mg of fluphenazine decanoate biweekly
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional dose of fluphenazine
Number of subjects: 36
Study: 31105027

Group type: EXPERIMENTAL
Intervention: bifrontal tDCS (2 mA, 30min, 22 sessions)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study: 28972794

Group type: EXPERIMENTAL
Intervention: Sparing both the ipsilateral and contralateral parotid glands (Group 1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sparing only the contralateral parotid gland (Group 2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sparing only the contralateral superficial parotid lobe (Group 3)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Not sparing any lobe of both parotid glands (Group 4)
Number of subjects: 88
Study: 25299703

Group type: EXPERIMENTAL
Intervention: Glass ionomer restorative system (Equia, GC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Microfilled hybrid composite (Gradia Direct Posterior, GC)
Number of subjects: 59